A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Trial Profile

A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Centanafadine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Euthymics Bioscience
  • Most Recent Events

    • 14 Dec 2016 According to a Neurovance media release, positive results from this trial will be used to support an FDA regulatory package for centanafadine.
    • 27 Jul 2016 Primary endpoint (Changes in Total Attention-Deficit Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Score) has been met, according to a Neurovance Inc. media release.
    • 27 Jul 2016 Results published in a Neurovance Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top